{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967691",
  "id": "02967691",
  "pages": 18,
  "price_sensitive": false,
  "date": "20250709",
  "time": "0922",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmnjf0w2f7pv.pdf",
  "summary": "**Material Information Summary:**  \n\n- **Asset Acquisition (Galidesivir):**  \n  - Acquired from BioCryst Pharmaceuticals (Nasdaq: BCRX) for upfront $550k USD.  \n  - Milestone payments: $500k USD (Phase 2 completion), $1M USD (NDA approval), $1.5M USD (Animal Rule approval).  \n  - Tiered royalties (5\u201310% net sales) and 25% of Priority Review Voucher (PRV) proceeds.  \n\n- **Clinical Progress:**  \n  - Phase 2a/b dengue trial completed; targeting Marburg virus under \"Animal Rule\" pathway (potential NDA within 12 months).  \n  - Broad-spectrum antiviral activity demonstrated in vitro/in vivo against 20+ RNA viruses (Ebola, Zika, Yellow Fever, etc.).  \n  - Phase 1 safety data established for intramuscular/intravenous routes.  \n\n- **Funding & Liquidity:**  \n  - Cash balance (31 March 2024): $4.82m AUD.  \n  - May 2025 capital raise: $3.6m AUD.  \n  - US DoD grant: $625k USD for dengue trial support.  \n\n- **Regulatory & Partnerships:**  \n  - Potential PRVs (valued ~$225m AUD each) upon FDA approval.  \n  - Targeting government stockpile programs and partnerships.  \n\n*[Note: Presentation contains forward-looking statements; no material financial/trading updates beyond disclosed data.]*",
  "usage": {
    "prompt_tokens": 4517,
    "completion_tokens": 314,
    "total_tokens": 4831,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:43:25.996335"
}